A New Heteroleptic Zn(II) Complex with Schiff Bases Sensitizes Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel

A New Heteroleptic Zn(II) Complex with Schiff Bases Sensitizes Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel

<b>Background/Objectives</b>: Triple-negative breast cancer (TNBC) is the most challenging molecular subtype of breast cancer (BC) in clinical practice, associated with a worse prognosis due to limited treatment strategies and its insensitivity to conventional drugs. Zinc is an important...

Full description

Bibliographic Details
Main Authors: Raiane Aparecida dos Santos Machado, Raoni Pais Siqueira, Fernanda Cardoso da Silva, André Carlos Pereira de Matos, Dayanne Silva Borges, Gislaine Gonçalves Rocha, Thais Cristina Prado de Souza, Rafael Aparecido Carvalho Souza, Clayton Rodrigues de Oliveira, Antônio G. Ferreira, Pedro Ivo da Silva Maia, Victor Marcelo Deflon, Carolina Gonçalves Oliveira, Thaise Gonçalves Araújo
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Pharmaceutics
Subjects:
Zinc(II)
MDA-MB-231
breast cancer
chemotherapy
Online Access:https://www.mdpi.com/1999-4923/16/12/1610

Internet

https://www.mdpi.com/1999-4923/16/12/1610

Similar Items